. 2013 Nov;22(11):915–929. doi: 10.1089/jwh.2013.4270

Table 4.

Cumulative Analyzed Incidence Rates for Clinical Outcomes in the Women's Health Initiative Calcium and Vitamin D Supplementation Trial: Stratified by Personal Use of Calcium Supplements (With or Without Vitamin D) at Calcium and Vitamin D Randomization

	Overall combined phases
	CaD		Placebo
	N	%	N	%	HR^*	(95% CI)^a	p-value^a
Hip fracture							0.28
No	153	0.16	180	0.20	0.84	(0.67, 1.04)
Yes	226	0.21	233	0.22	0.96	(0.80, 1.16)
Vertebral fracture^b							0.76
No	172	0.18	192	0.21	0.89	(0.72, 1.09)
Yes	274	0.25	316	0.29	0.84	(0.71, 0.99)
Total fracture^b							0.71
No	1765	2.08	1733	2.09	1.00	(0.93, 1.06)
Yes	2248	2.31	2285	2.35	0.98	(0.92, 1.04)
Invasive colorectal cancer							0.18
No	111	0.12	131	0.14	0.85	(0.66, 1.10)
Yes	145	0.13	136	0.13	1.05	(0.83, 1.32)
Invasive breast cancer							0.16
No	359	0.39	366	0.41	0.96	(0.83, 1.11)
Yes	492	0.47	450	0.42	1.10	(0.97, 1.25)
In situ breast cancer							0.17
No	76	0.08	106	0.12	0.69	(0.52, 0.93)
Yes	122	0.12	132	0.13	0.91	(0.71, 1.16)
Total cancer							0.04
No	1126	1.27	1204	1.40	0.91	(0.84, 0.99)
Yes	1428	1.40	1413	1.38	1.02	(0.94, 1.09)
Coronary heart disease							0.34
No	453	0.49	415	0.46	1.08	(0.95, 1.23)
Yes	424	0.40	430	0.40	0.99	(0.86, 1.13)
Coronary heart disease death^c							0.55
No	130	0.14	136	0.15	0.95	(0.75, 1.22)
Yes	138	0.13	129	0.12	1.03	(0.81, 1.32)
Clinical myocardial infarction							0.17
No	347	0.38	309	0.34	1.11	(0.95, 1.29)
Yes	312	0.29	328	0.31	0.96	(0.82, 1.12)
Stroke							0.30
No	340	0.37	305	0.34	1.11	(0.95, 1.30)
Yes	350	0.33	354	0.33	0.99	(0.85, 1.15)
Cardiovascular disease death							0.60
No	262	0.28	257	0.28	1.00	(0.84, 1.19)
Yes	287	0.26	268	0.25	1.06	(0.90, 1.25)
Total death							0.38
No	852	0.91	845	0.92	0.99	(0.90, 1.09)
Yes	923	0.85	978	0.90	0.94	(0.86, 1.02)
Global index							0.55
No	1325	1.46	1379	1.56	0.94	(0.87, 1.02)
Yes	1607	1.54	1616	1.54	0.97	(0.91, 1.04)

^{^a}

From a proportional hazards model stratified by prevalent condition (where appropriate), age, hormone therapy and diet modification randomization arm, and trial phase (time-dependent). Time to event equals 0 on date of randomization.

^{^b}

All nonhip fractures use adjudicated data during the clinical trial and self-reported data thereafter.

^{^c}

Coronary heart disease death includes definite and possible coronary heart disease death.